These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
436 related articles for article (PubMed ID: 31819443)
1. Co-Delivery of Curcumin and Paclitaxel by "Core-Shell" Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer. Zhao MD; Li JQ; Chen FY; Dong W; Wen LJ; Fei WD; Zhang X; Yang PL; Zhang XM; Zheng CH Int J Nanomedicine; 2019; 14():9453-9467. PubMed ID: 31819443 [TBL] [Abstract][Full Text] [Related]
2. A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway. Wang X; Xiong T; Cui M; Li N; Li Q; Zhu L; Duan S; Wang Y; Guo Y J Nanobiotechnology; 2021 Dec; 19(1):444. PubMed ID: 34949180 [TBL] [Abstract][Full Text] [Related]
3. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance. Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509 [TBL] [Abstract][Full Text] [Related]
4. Investigation on vitamin e succinate based intelligent hyaluronic acid micelles for overcoming drug resistance and enhancing anticancer efficacy. Hou L; Tian C; Chen D; Yuan Y; Yan Y; Huang Q; Zhang H; Zhang Z Eur J Pharm Sci; 2019 Dec; 140():105071. PubMed ID: 31525433 [TBL] [Abstract][Full Text] [Related]
5. Systematic evaluation of multifunctional paclitaxel-loaded polymeric mixed micelles as a potential anticancer remedy to overcome multidrug resistance. Zhang J; Zhao X; Chen Q; Yin X; Xin X; Li K; Qiao M; Hu H; Chen D; Zhao X Acta Biomater; 2017 Mar; 50():381-395. PubMed ID: 27956367 [TBL] [Abstract][Full Text] [Related]
6. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion. Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386 [TBL] [Abstract][Full Text] [Related]
7. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer. Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492 [TBL] [Abstract][Full Text] [Related]
8. Gene/paclitaxel co-delivering nanocarriers prepared by framework-induced self-assembly for the inhibition of highly drug-resistant tumors. Wang C; Guan W; Peng J; Chen Y; Xu G; Dou H Acta Biomater; 2020 Feb; 103():247-258. PubMed ID: 31846802 [TBL] [Abstract][Full Text] [Related]
9. Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution. Liu Y; Sun J; Lian H; Cao W; Wang Y; He Z J Pharm Sci; 2014 May; 103(5):1538-47. PubMed ID: 24619562 [TBL] [Abstract][Full Text] [Related]
10. Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer. Talekar M; Ouyang Q; Goldberg MS; Amiji MM Mol Cancer Ther; 2015 Jul; 14(7):1521-31. PubMed ID: 25964202 [TBL] [Abstract][Full Text] [Related]
11. Amphiphilic Copolymeric Micelles for Doxorubicin and Curcumin Co-Delivery to Reverse Multidrug Resistance in Breast Cancer. Lv L; Qiu K; Yu X; Chen C; Qin F; Shi Y; Ou J; Zhang T; Zhu H; Wu J; Liu C; Li G J Biomed Nanotechnol; 2016 May; 12(5):973-85. PubMed ID: 27305819 [TBL] [Abstract][Full Text] [Related]
12. Co-delivery of Paclitaxel/Atovaquone/Quercetin to regulate energy metabolism to reverse multidrug resistance in ovarian cancer by PLGA-PEG nanoparticles. Lu Q; Gao W; Chen Z; Liu Z; Wang J; Zeng L; Hu X; Zheng E; Zhang Q; Song H Int J Pharm; 2024 Apr; 655():124028. PubMed ID: 38518871 [TBL] [Abstract][Full Text] [Related]
13. Polyethyleneimine- -Tocopherol Hydrogen Succinate/Hyaluronic Acid-Quercetin (PEI-TOS/HA-QU) Core-Shell Micelles Delivering Paclitaxel for Combinatorial Treatment of MDR Breast Cancer. Qian J; Liu S; Yang T; Xiao Y; Sun J; Zhao J; Zhang Z; Xie Y J Biomed Nanotechnol; 2021 Mar; 17(3):382-398. PubMed ID: 33875073 [TBL] [Abstract][Full Text] [Related]
14. A multifunctional lipid nanoparticle for co-delivery of paclitaxel and curcumin for targeted delivery and enhanced cytotoxicity in multidrug resistant breast cancer cells. Baek JS; Cho CW Oncotarget; 2017 May; 8(18):30369-30382. PubMed ID: 28423731 [TBL] [Abstract][Full Text] [Related]
15. Comparison of hyaluronic acid-based micelles and polyethylene glycol-based micelles on reversal of multidrug resistance and enhanced anticancer efficacy in vitro and in vivo. Wang J; Li Y; Wang L; Wang X; Tu P Drug Deliv; 2018 Nov; 25(1):330-340. PubMed ID: 29350064 [TBL] [Abstract][Full Text] [Related]
16. Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance. Lei M; Ma G; Sha S; Wang X; Feng H; Zhu Y; Du X Drug Deliv; 2019 Dec; 26(1):262-272. PubMed ID: 30856352 [TBL] [Abstract][Full Text] [Related]
17. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer. Wu J; Wang Q; Dong X; Xu M; Yang J; Yi X; Chen B; Dong X; Wang Y; Lou X; Xia F; Wang S; Dai J Theranostics; 2021; 11(8):3710-3724. PubMed ID: 33664857 [TBL] [Abstract][Full Text] [Related]
18. Paclitaxel-loaded poly(n-butylcyanoacrylate) nanoparticle delivery system to overcome multidrug resistance in ovarian cancer. Ren F; Chen R; Wang Y; Sun Y; Jiang Y; Li G Pharm Res; 2011 Apr; 28(4):897-906. PubMed ID: 21184150 [TBL] [Abstract][Full Text] [Related]
19. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery. Gu J; Fang X; Hao J; Sha X Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500 [TBL] [Abstract][Full Text] [Related]
20. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. Yang X; Iyer AK; Singh A; Choy E; Hornicek FJ; Amiji MM; Duan Z Sci Rep; 2015 Feb; 5():8509. PubMed ID: 25687880 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]